These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16761906)

  • 1. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
    Dranitsaris G; Vincent M; Crowther M
    Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
    Dranitsaris G; Shane L; Burgers L; Woodruff S
    Clin Appl Thromb Hemost; 2016 Oct; 22(7):617-26. PubMed ID: 27436663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.
    Dranitsaris G; Stumpo C; Smith R; Bartle W
    Am J Cardiovasc Drugs; 2009; 9(1):45-58. PubMed ID: 19178131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
    Dranitsaris G; Shane LG; Galanaud JP; Stemer G; Debourdeau P; Woodruff S
    Support Care Cancer; 2017 Jul; 25(7):2093-2102. PubMed ID: 28204995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
    Heerey A; Suri S
    Pharmacoeconomics; 2005; 23(9):927-44. PubMed ID: 16153135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis.
    Dranitsaris G; Shane LG; Crowther M; Feugere G; Woodruff S
    Clinicoecon Outcomes Res; 2017; 9():65-73. PubMed ID: 28138260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
    Goodin S
    Am J Health Syst Pharm; 2005 Nov; 62(22 Suppl 5):S10-3. PubMed ID: 16286363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
    J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis.
    Marchetti M; Pistorio A; Barone M; Serafini S; Barosi G
    Am J Med; 2001 Aug; 111(2):130-9. PubMed ID: 11498067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL
    J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].
    Arreola-Ornelas H; Rosado-Buzzo A; García-Mollinedo L; Dorantes Aguilar J; Muciño-Ortega E; Mould-Quevedo JF
    Cir Cir; 2012; 80(5):411-8. PubMed ID: 23351443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses.
    El-Hamamsy MH; Elsisi GH; Eldessouki R; Elmazar MM; Taha AS; Awad BF; Elmansy H
    Appl Health Econ Health Policy; 2016 Aug; 14(4):431-440. PubMed ID: 27028445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
    Seaman CD; Smith KJ; Ragni MV
    Thromb Res; 2013; 132(6):647-51. PubMed ID: 24139508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism.
    Aujesky D; Smith KJ; Cornuz J; Roberts MS
    Thromb Haemost; 2005 Mar; 93(3):592-9. PubMed ID: 15735815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of extended-duration antithrombotic prophylaxis after total hip arthroplasty.
    Skedgel C; Goeree R; Pleasance S; Thompson K; O'brien B; Anderson D
    J Bone Joint Surg Am; 2007 Apr; 89(4):819-28. PubMed ID: 17403806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness.
    Dranitsaris G; Shane LG; Woodruff S
    J Oncol Pharm Pract; 2019 Jan; 25(1):68-75. PubMed ID: 28857713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of venous thromboembolism in patients with cancer: role of dalteparin.
    Linkins LA
    Vasc Health Risk Manag; 2008; 4(2):279-87. PubMed ID: 18561503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
    Kaufman JL
    N Engl J Med; 2003 Oct; 349(14):1385-7; author reply 1385-7. PubMed ID: 14526769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.